Trials / Withdrawn
WithdrawnNCT04667182
A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes
Meal-centric Insulin Dosing for Optimized Post-Prandial Glucose Control in People Using Multiple Daily Injections
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 25 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine whether combining meal, glucose and insulin data in a web-based system will improve management of type 1 (T1D) and type 2 diabetes (T2D). No study drug will be given. The study will last about 18 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Meal-Tagging App and Web-based Portal: | Meal tagging app to capture frequently eaten meals and test meals for 18 weeks. |
| DEVICE | Fitness Tracker | Fitness tracker will be worn around the clock for 18 weeks. |
Timeline
- Start date
- 2021-01-25
- Primary completion
- 2021-12-06
- Completion
- 2021-12-06
- First posted
- 2020-12-14
- Last updated
- 2021-09-17
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04667182. Inclusion in this directory is not an endorsement.